Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Before Tuesday, 90 percent of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) analysts were buying the stock. But one analyst has diluted the decisive bullishness with rare ambivalence.
The Rating
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Goldman Sachs analyst Dana Flanders initiated coverage on Alder with a Neutral rating and $17 price target.
The Thesis
The rating reflects ambiguity around commercial questions for IV eptinezumab, a calcitonin gene-related peptide monoclonal antibody inhibitor that Flanders said he expects to launch in the second half of 2019. (See the analyst's track record here.)
The analyst considers the significant and underserved migraine market a $5-billion opportunity, but also a highly competitive one. Amgen, Inc. (NASDAQ:AMGN), Eli Lilly And Co (NYSE:LLY) and Teva Pharmaceuticals Industries Ltd (ADR) ADR (NYSE:TEVA) are developing competing mAbs.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Goldman Sachs forecast five-year sales of around $650 million.
“We spoke with a neurologist at a leading academic headache center, who did not view current data supporting meaningful differentiation across CGRP agents,” Flanders said in a note. “However, she noted unmet need for new migraine therapies, was positive on overall CGRP efficacy and expected 25-percent to 33-percent uptake across eligible patients at her institution in four to five years.”
The estimates assume positive reimbursement conditions and the establishment of the long-term safety of the therapy.
Price Action
Alder Pharma shares were down 2 percent at the time of publication Tuesday.
Related Links:
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
The Size Effect Is Working With Health Care ETFs
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.